Tivic Health Systems, Inc. (TIVC)
$
0.93
-0.06 (-6.45%)
Key metrics
Financial statements
Free cash flow per share
-4.6238
Market cap
1.1 Million
Price to sales ratio
2.2223
Debt to equity
0
Current ratio
5.8621
Income quality
0.8096
Average inventory
143.5 Thousand
ROE
-2.0220
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Tivic Health Systems Inc. operates as a bioelectronic device company, specializing in non-invasive neuromodulation products aimed at treating inflammatory conditions. Its flagship product, ClearUP, is a medical device designed to alleviate sinus and nasal inflammation, which positions the company as an innovative contributor to healthcare solutions. The earnings per share (EPS) is reported at -$19.67 indicating the company's profitability on a per-share basis. Moreover, the net total of other income and expenses is $6,000.00 reflecting non-core financial activities that may influence its financial health. The overall costs and expenses for the company stand at $6,441,000.00 showcasing its total spending, while operating expenses amount to $5,663,000.00 encompassing a range of operational costs incurred during its activities. The operating income ratio is -7.26 providing insight into the company's operational profitability margin, which is crucial for evaluating its financial effectiveness in the market. As a small-cap player with a market capitalization of $1,007,212.00 Tivic Health is considered a notable entity within the industry landscape. The stock is affordable at $3.07 making it suitable for budget-conscious investors seeking to engage with the market. The stock also has a high average trading volume of 252,693.00 indicating strong liquidity, which is essential for investors looking to buy or sell shares without significant price fluctuations. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape and fostering advancements that may benefit consumers. Additionally, it belongs to the Healthcare sector, driving innovation and growth, which underscores its potential impact on the healthcare ecosystem. Through strategic initiatives and consumer outreach via platforms like Amazon.com and Walmart.com, Tivic Health Systems, Inc. continues to expand its market presence and cater to the demands of its customer base.
Is Tivic Health Systems, Inc. (TIVC) a good investment?
Investing in Tivic Health Systems, Inc. (TIVC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Tivic Health Systems, Inc. (TIVC)'s stock forecast?
Analysts predict Tivic Health Systems, Inc. stock to fluctuate between $0.72 (low) and $13.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Tivic Health Systems, Inc.'s market capitalization?
As of 2026-03-27, Tivic Health Systems, Inc.'s market cap is $1,007,212, based on 1,083,257 outstanding shares.
How does Tivic Health Systems, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Tivic Health Systems, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Tivic Health Systems, Inc. (TIVC) stock?
To buy Tivic Health Systems, Inc. (TIVC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TIVC. Place an order (Market, Limit, etc.).
What is the best time to invest in Tivic Health Systems, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Tivic Health Systems, Inc. stock ever split?
Tivic Health Systems, Inc.'s last stock split was 1:17 on 2025-03-07.
How did Tivic Health Systems, Inc. perform in the last earnings report?
Revenue: $780,000 | EPS: -$19.67 | Growth: -88.87%.
Where can I find Tivic Health Systems, Inc.'s investor relations reports?
Visit https://www.tivichealth.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Tivic Health Systems, Inc.?
You can explore historical data from here
What is the all-time high and low for Tivic Health Systems, Inc. stock?
All-time high: $11,050 (2021-11-11) | All-time low: $0.72 (2026-03-09).
What are the key trends affecting Tivic Health Systems, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
Presentation will Cover Recent Corporate Milestones Including Securing Agreement with NIAID SAN ANTONIO, TX / ACCESS Newswire / March 27, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced that its newly appointed Chief Executive Officer, Michael K Handley, will deliver a corporate update at the Emerging Growth Virtual Conference taking place April 1-2, 2026. During the virtual conference, Mr.
accessnewswire.com
Armed Forces Radiobiology Research Institute (AFRRI) Will Conduct the Gastrointestinal Acute Radiation Syndrome (GI-ARS) Study SAN ANTONIO, TX / ACCESS Newswire / March 26, 2026 / Tivic Health Systems Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to sponsor and conduct a series of preclinical studies evaluating Entolimod™ for gastrointestinal acute radiation syndrome (GI-ARS). The program is expected to support Tivic's development strategy for Entolimod™ as a medical countermeasure for acute radiation syndrome (ARS).
accessnewswire.com
SAN ANTONIO, TX / ACCESS Newswire / March 24, 2026 / Tivic Health Systems (Nasdaq:TIVC) Dear Valued Shareholders, As I assume the role of Chief Executive Officer at Tivic, my immediate priority is to establish a transparent dialogue with you regarding our current standing, our strategic pivot, and the long-term vision we are executing. First, I want to thank the Board of Directors for their confidence and support.
accessnewswire.com
SAN ANTONIO, TX / ACCESS Newswire / March 20, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it will report its year-end financial results for 2025 via pre-recorded conference call and webcast on Wednesday, March 25, 2026 at 1:30 PM PT / 4:30 PM ET. Conference Call and Webcast Information Teleconference Details: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 910220 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53678 An audio replay of the call will be available for the next 90 days from the investor page on the Tivic website at https://tivichealth.com/investor/.
accessnewswire.com
SAN FRANCISCO, CA / ACCESS Newswire / March 4, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC) ("Tivic" or the "Company"), a late-stage immunotherapeutics company, today announced that its Board of Directors has appointed Michael K. Handley as Chief Executive Officer of Tivic, effective immediately.
accessnewswire.com
Initial presentation on January 26, 2026 s howcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure. FREMONT, CA / ACCESS Newswire / February 18, 2026 / Tivic (Nasdaq:TIVC), a late-stage immuno-therapeutics company, today announced that a second, follow-up meeting with the Biomedical Advanced Research and Development Authority (BARDA) has been scheduled for March 10, 2026, to continue discussions focused on clinical data and the potential for funding and, ultimately, stockpiling Entolimod™ for Acute Radiation Syndrome (ARS).
accessnewswire.com
January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure BARDA has requested a follow-up meeting to continue the discussion on the potential utility of Entolimod as a drug for the Strategic National Stockpile Showcased clinical results, regulatory progression, and manufacturing readiness accelerated by newly formed subsidiary Velocity Bioworks™ FREMONT, CA / ACCESS Newswire / January 28, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it delivered an invited presentation at a TechWatch meeting with the Biomedical Advanced Research and Development Authority (BARDA) on January 26, 2026, with select members of the Department of Defense (DoD), Defense Threat Reduction Agency (DTRA), National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID). The company presented key clinical and manufacturing readiness data for Tivic's Toll-like Receptor 5 (TLR5) agonist, Entolimod™, underscoring its potential use as a radiation countermeasure, as well as progress on manufacturing readiness that has been accelerated by newly formed subsidiary Velocity Bioworks.
accessnewswire.com
Presentation will Cover Recent Corporate Milestones Including Acceleration of Manufacturing Readiness for Entolimod™ FREMONT, CA / ACCESS Newswire / January 20, 2026 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage immunotherapeutics company, today announced that its CEO will provide a corporate update focused on recent developments in its advancement of Entolimod ™ during the Emerging Growth Virtual Conference on January 21 and 22, 2026 WHO: Jennifer Ernst, Chief Executive Officer WHERE: January 22, 2026 WHEN: 4:10 - 4:20 Eastern Time During the virtual conference update, Ms. Ernst will highlight recent company developments, including scale-up validation for Entolimod manufacturing and the vertical integration of Velocity Bioworks-a San Antonio-based contract development and manufacturing organization which provides the company with in-house manufacturing capability and new potential revenue streams.
seekingalpha.com
Tivic Health Systems, Inc. (TIVC) Discusses Acquisition of Biomanufacturing Assets and Strategic Transformation Transcript
accessnewswire.com
Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™ Financing led by 3i, LP includes $16M debt financing for the purchase of assets and up to $75M in preferred convertible equity available for therapeutics commercialization and corporate growth initiatives FREMONT, CA AND SAN ANTONIO, TX / ACCESS Newswire / December 11, 2025 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a diversified therapeutics company, today announced it has acquired the strategic manufacturing and development assets of Scorpius Holdings, Inc. and is launching Velocity Bioworks™, a wholly owned subsidiary of Tivic, to provide contract development and manufacturing services to Tivic and other companies. Strategic advantages of this acquisition and the formation of Velocity Bioworks include: Secures a robust US-based manufacturing site for Tivic's lead drug candidate Entolimod™ as the company moves towards a Biologics License Application (BLA) with the U.S. Food & Drug Administration.
See all news
